1-4 of 4
Tetsuya Mitsudomi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer

Kenichi Suda, Isao Murakami, Hui Yu, Jihye Kim, Aik-Choon Tan, Hiroshi Mizuuchi, Leslie Rozeboom, Kim Ellison, Christopher J. Rivard, Tetsuya Mitsudomi, Fred R. Hirsch
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (10): 2257–2265.
https://doi.org/10.1158/1535-7163.MCT-17-1279
Published: 01 October 2018
View article titled, CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer
Open the PDF for CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer

Yoshihisa Kobayashi, Koichi Azuma, Hiroki Nagai, Young Hak Kim, Yosuke Togashi, Yuichi Sesumi, Masato Chiba, Masaki Shimoji, Katsuaki Sato, Kenji Tomizawa, Toshiki Takemoto, Kazuto Nishio, Tetsuya Mitsudomi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (2): 357–364.
https://doi.org/10.1158/1535-7163.MCT-16-0407
Published: 02 February 2017
View article titled, Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer
Open the PDF for Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer

Takayuki Nakagawa, Shinji Takeuchi, Tadaaki Yamada, Shigeki Nanjo, Daisuke Ishikawa, Takako Sano, Kenji Kita, Takahiro Nakamura, Kunio Matsumoto, Kenichi Suda, Tetsuya Mitsudomi, Yoshitaka Sekido, Toshimitsu Uenaka, Seiji Yano
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (10): 2149–2157.
https://doi.org/10.1158/1535-7163.MCT-12-0195
Published: 09 October 2012
View article titled, Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in <em>EGFR</em>-Mutant Lung Cancer
Open the PDF for Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in <em>EGFR</em>-Mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A178: Role of tumor and host‐derived HGF in drug resistance to EGFR inhibitors in EGFR activating mutation‐positive lung cancer

Soji Kakiuchi, Seiji Yano, Wei Wang, Qi Li, Tadaaki Yamada, Kunio Matsumoto, Masaki Hanibuchi, Tetsuya Mitsudomi, Yasushi Yatabe, Takuya Kuramoto, Koji Otsuka, Yasuhiko Nishioka, Saburo Sone
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A178.
https://doi.org/10.1158/1535-7163.TARG-09-A178
Published: 10 December 2009
View article titled, Abstract A178: Role of tumor and host‐derived HGF in drug resistance to EGFR inhibitors in EGFR activating mutation‐positive lung cancer